Skip to main content

Julie D Saba

NIH Rank #8402
  • R01 Holder
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1866596Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Pediatrics

NIH Funding · FY2025

Linked Award Amount
$1.7M
Full award amounts, FY2025
Award Records
6
Records listing this PI
Award-Linked Rank
#8,402
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Julie D Saba. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Julie D Saba as a PI. Multi-PI records show the full award amount for context.

  • 5R01HD113778-02R01
    Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis
    $682.2K
    award amount
  • 5R61HL171786-02R61
    Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling
    $565.3K
    award amount
  • 1R21OD037868-01R21
    Characterizing a novel mouse model linking sphingolipid metabolism to multi-organ fibrosis
    $246K
    award amount
  • 3R01HD113778-02S1R01
    Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis
    $105K
    award amount
  • 3R61HL171786-01S1R61
    Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling
    $62.8K
    award amount
  • 3R01HD113778-01S1R01
    Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis
    $54.9K
    award amount

Award organization

Organizations that administered FY2025 awards listing Julie D Saba as a PI.

FY2025 award administered by University of California, San Francisco (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of California, San Francisco
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6968
  5. 2025
    $2M Cumulative Funding
  6. 2025
    R01 Grant Holder